WEST virginia Legislature

2017 regular session

Introduced

House Bill 2633

By Delegates Folk, McGeehan, Paynter, Miley, Barrett, Phillips, Wilson, Sponaugle and Ellington

[Introduced February 21, 2017;
Referred to the Committee on Education then Health and Human Resources.]

A BILL to amend of the Code of West Virginia, 1931, as amended, by adding thereto a new section, designated §18B-18B-3, relating to requiring state institutions of higher education to conduct Phase 3 clinical research studies for any cancer treatment or technology that has been approved for Phase 3 study by the United States Food and Drug Administration.

Be it enacted by the Legislature of West Virginia:

That the Code of West Virginia, 1931, as amended, be amended, by adding thereto a new section, designated §18B-18B-3, to read as follows:

ARTICLE 18B. SCIENCE AND RESEARCH COUNCIL.

§18B-18B-3. Phase 3 clinic studies for cancer treatments.

(a)  A state institution of higher education with a clinical research program shall, at the request of a sponsor or a sponsor-investigator, conduct Phase 3 clinical research studies for any cancer treatment or technology that has been approved for Phase 3 clinical study by the United States Food and Drug Administration.

(b) For the purposes of this section, “clinical research program” means a program in which a state institution of higher education, through its students or faculty, acts as an investigator in clinical trials for pharmaceutical or medical treatments or technologies and includes, but is not limited to, the Appalachian Clinical and Translational Science Institute of Marshall University and the Clinical Trial Research Unit and Clinical and Pharmacologic Research Center of West Virginia University.  All other terms in this section shall have the same meaning ascribed to them by 21 C.F.R. § 50.3 and 21 C.F.R. §312.21.

NOTE: The purpose of this bill is to require state institutions of higher education to conduct Phase 3 clinical research studies for any cancer treatment that has been approved for Phase 3 study by the United States Food and Drug Administration.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.